The lung is a uniquely vulnerable organ. Residing at the interface of the body and the environment, the lung is optimized for gas exchange, having a very thin, delicate epithelium, abundant blood flow, and a vast surface area. Inherent in this structure is an enormous immunological burden from pathogens, allergens, and pollutants resident in the 11,000 liters of air inhaled daily. Fortunately, protective immune mechanisms act locally in the lung to facilitate clearance of inhaled pathogens and to modulate inflammatory responses. These defensive mechanisms include both innate (nonantibody-mediated) and adaptive (antibody-mediated) systems. The purpose of this commentary is to review briefly the functions of one unique lung innate immune system, pulmonary surfactant, and to highlight the recent findings of Wu et al. (1) described in this issue of the JCI. Wu and colleagues report a new and intriguing innate immune function of surfactant: direct antimicrobial activity.
Pulmonary surfactant and lung host defense
Pulmonary surfactant is a lipoprotein complex that is synthesized and secreted by the alveolar type II epithelial cell and the airway Clara cell into the thin liquid layer that lines the epithelium (reviewed in ref. 2) . Once in the extracellular space, surfactant carries out two distinct functions. First, it reduces surface tension at the airliquid interface of the lung, a function that requires an appropriate mix of surfactant lipids and the hydrophobic proteins, surfactant protein B (SP-B) and SP-C (3). Second, surfactant plays a role in host defense against infection and inflammation (4). Two of the surfactant proteins, SP-A and SP-D, are members of the collectin protein family (5, 6) , which includes the liver-derived serum mannose binding lectin. Collectins have in common an N-terminal collagen-like region and a C-terminal lectin domain that binds carbohydrates in a calcium-dependent manner ( Figure  1 ). The C-type lectin domains are arrayed with spatial orientation (7) that confers unique carbohydrate specificities, and their preferential binding sites are nonhost oligosaccharides, such as those found on bacterial and viral surfaces (8) .
The most well-defined function of the collectins is their ability to opsonize pathogens, including bacteria and viruses, and to facilitate phagocytosis by innate immune cells such as macrophages and monocytes. SP-A and SP-D also regulate production of inflammatory mediators (reviewed in ref. 
Newly defined antibacterial functions of surfactant
Data presented in the article by Wu and coworkers in this issue of the JCI (1) show convincingly that, in addition to facilitating pathogen uptake and killing by immune cells, SP-A and SP-D are directly antimicrobial, that is, they kill bacteria in the absence of immune effector cells (Figure 2 ). This conclusion is greatly strengthened by the multiple experimental approaches employed in the study. For example, Wu et al. demonstrate that exposure of Escherichia coli to SP-A and SP-D enhanced nuclear staining with propidium iodide, increased permeability to the antibiotic actinomycin D, and augmented release of proteins from the bacteria. Interestingly, inhibition of microbial growth was at least partly independent of collectin-mediated aggregation of bacteria and appears to involve damage to the bacterial cell membrane by the C-type lectin domains. Although SP-A and SP-D inhibited bacterial growth of a number of laboratory and clinical isolates, the factors that determine their specificity and the mechanism by which they increase membrane permeability are not known and will be important future avenues of investigation.
Future directions: surfactant therapy for infectious and inflammatory lung diseases?
Deficiencies of surfactant have been associated with a variety of lung diseases in both adults and infants. For example, infants born before their lungs have matured sufficiently suffer from respiratory distress syndrome due to the inability of their immature type II cells to synthesize adequate amounts of functional surfactant. Treatment with surfactant replacement therapies that include lipids and SP-B and/or SP-C have been highly efficacious in improving lung function in preterm newborns (11) .
Surfactant inactivation and deficiencies have also been associated with a variety of adult lung diseases including pneumonia, asthma, and acute respiratory distress syndrome (ARDS) (reviewed in refs. 12, 13). Clinical trials have been undertaken for treatment of ARDS with surfactant replacement therapies containing either lipids or lipids plus SP-B and/or SP-C (14) . However, these treatments have not been as effective in treating adult ARDS compared to infant respiratory distress syndrome. The new data presented by Wu and coworkers showing that SP-A and SP-D have direct bactericidal activity, in addition to their welldescribed opsonic activity and ability to regulate inflammatory mediator production, suggest that supplementation of the lipid-based therapies with SP-A and/or SP-D would further enhance their ability to treat infectious and inflammatory lung diseases (1) . Importantly, recent studies have demonstrated that these proteins are expressed at extrapulmonary sites (15) (16) (17) , raising the intriguing possibility that they may be efficacious for treatment of inflammatory and infectious diseases in other organs as well.
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